{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Capsules&page=96",
    "query": {
      "intervention": "Control Capsules",
      "page": 96
    },
    "page_size": 10
  },
  "pagination": {
    "page": 96,
    "page_size": 10,
    "total_count": 2912,
    "total_pages": 292,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Capsules&page=97&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Capsules&page=95&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-09T23:17:22.935Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03151811",
      "title": "A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Melflufen",
          "type": "DRUG"
        },
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oncopeptides AB",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 495,
      "start_date": "2017-06-12",
      "completion_date": "2023-02-03",
      "has_results": true,
      "last_update_posted_date": "2024-01-30",
      "last_synced_at": "2026-11-09T23:17:22.935Z",
      "location_count": 14,
      "location_summary": "Tucson, Arizona • Fresno, California • Gainesville, Florida + 11 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Orange City",
          "state": "Florida"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03151811"
    },
    {
      "nct_id": "NCT01741701",
      "title": "A Pilot Study of Oxaloacetate in Subjects With Treated PD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "Oxaloacetate (OAA)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Kansas Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2012-12",
      "completion_date": "2014-10",
      "has_results": true,
      "last_update_posted_date": "2016-03-17",
      "last_synced_at": "2026-11-09T23:17:22.935Z",
      "location_count": 1,
      "location_summary": "Kansas City, Kansas",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01741701"
    },
    {
      "nct_id": "NCT00658372",
      "title": "A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Generalized Anxiety Disorder"
      ],
      "interventions": [
        {
          "name": "PD 0332334",
          "type": "DRUG"
        },
        {
          "name": "Paroxetine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 360,
      "start_date": "2008-05",
      "completion_date": "2009-03",
      "has_results": false,
      "last_update_posted_date": "2012-11-16",
      "last_synced_at": "2026-11-09T23:17:22.935Z",
      "location_count": 29,
      "location_summary": "Arcadia, California • Costa Mesa, California • Escondido, California + 25 more",
      "locations": [
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00658372"
    },
    {
      "nct_id": "NCT05599932",
      "title": "Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatic Impairment"
      ],
      "interventions": [
        {
          "name": "Siremadlin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 38,
      "start_date": "2022-12-02",
      "completion_date": "2023-09-18",
      "has_results": false,
      "last_update_posted_date": "2025-07-09",
      "last_synced_at": "2026-11-09T23:17:22.935Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • Orlando, Florida • San Antonio, Texas",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05599932"
    },
    {
      "nct_id": "NCT03561701",
      "title": "A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Recurrent Vulvovaginal Candidiasis"
      ],
      "interventions": [
        {
          "name": "Oteseconazole (VT-1161)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mycovia Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "12 Years and older · Female only"
      },
      "enrollment_count": 425,
      "start_date": "2018-08-23",
      "completion_date": "2021-08-03",
      "has_results": true,
      "last_update_posted_date": "2026-02-17",
      "last_synced_at": "2026-11-09T23:17:22.935Z",
      "location_count": 14,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Homestead",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03561701"
    },
    {
      "nct_id": "NCT02007512",
      "title": "Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "exemestane",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for enzalutamide)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 247,
      "start_date": "2013-12-16",
      "completion_date": "2024-08-23",
      "has_results": true,
      "last_update_posted_date": "2025-09-02",
      "last_synced_at": "2026-11-09T23:17:22.935Z",
      "location_count": 89,
      "location_summary": "Aurora, Colorado • Colorado Springs, Colorado • Lakewood, Colorado + 54 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02007512"
    },
    {
      "nct_id": "NCT01092065",
      "title": "Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "AFQ056 with L-dopa",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "30 Years to 80 Years"
      },
      "enrollment_count": 23,
      "start_date": "2010-03",
      "completion_date": "2011-07",
      "has_results": false,
      "last_update_posted_date": "2020-12-23",
      "last_synced_at": "2026-11-09T23:17:22.935Z",
      "location_count": 4,
      "location_summary": "Sunnyvale, California • Englewood, Colorado • Indianapolis, Indiana + 1 more",
      "locations": [
        {
          "city": "Sunnyvale",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01092065"
    },
    {
      "nct_id": "NCT01432236",
      "title": "A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Fibromyalgia"
      ],
      "interventions": [
        {
          "name": "Pregabalin",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 197,
      "start_date": "2011-10",
      "completion_date": "2013-07",
      "has_results": true,
      "last_update_posted_date": "2021-01-22",
      "last_synced_at": "2026-11-09T23:17:22.935Z",
      "location_count": 26,
      "location_summary": "Tucson, Arizona • Orange, California • Santa Ana, California + 21 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01432236"
    },
    {
      "nct_id": "NCT07506564",
      "title": "Acute Impact of Non-Sugar Sweeteners (Sucralose and Aspartame)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Prediabetes"
      ],
      "interventions": [
        {
          "name": "non-sugar sweeteners - Sucralose",
          "type": "OTHER"
        },
        {
          "name": "non-sugar sweetener - aspartame",
          "type": "OTHER"
        },
        {
          "name": "Non-sugar sweetener - control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Virginia Polytechnic Institute and State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2022-08-01",
      "completion_date": "2025-05-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-01",
      "last_synced_at": "2026-11-09T23:17:22.935Z",
      "location_count": 1,
      "location_summary": "Blacksburg, Virginia",
      "locations": [
        {
          "city": "Blacksburg",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07506564"
    },
    {
      "nct_id": "NCT00484198",
      "title": "Study of Rivoglitazone in Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Pioglitazone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Rivoglitazone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1912,
      "start_date": "2007-04-23",
      "completion_date": "2009-02-12",
      "has_results": true,
      "last_update_posted_date": "2021-07-27",
      "last_synced_at": "2026-11-09T23:17:22.935Z",
      "location_count": 70,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Hoover, Alabama + 67 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Hoover",
          "state": "Alabama"
        },
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00484198"
    }
  ]
}